NCT01285700

Dose Finding Study of Recombinant Human Alpha-mannosidase for the Treatment of Patients With Alpha-mannosidosis

A Single Center, Randomized, Open-label, Multiple-dose Study of the Efficacy and Long-term Safety of rhLAMAN (Recombinant Human Alpha-mannosidase or Lamazym) for the Treatment of Patients With Alpha-mannosidosis.

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: Zymenex A/S · Industry
• Sex: All
• Age: 5 Years – 21 Years
• Healthy volunteers: Not accepted

Summary

This is a single-center, open-label, multiple-dose study of the efficacy and long-term safety of Lamazym for the treatment of patients with alpha-mannosidosis.

Conditions

• Alpha Mannosidosis

Interventions

Type	Name	Description
DRUG	Lamazym	ERT, infusion weekly

Timeline

• Start date: 2011-01-01
• Primary completion: 2012-01-01
• Completion: 2012-11-01
• First posted: 2011-01-28
• Last updated: 2012-09-26

Locations

1 site across 1 country: Denmark